RESUMO
Possible interactions between the new non-steroidal antirheumatic drug Sulindac and a coumarin derivative have been investigated. 20 subjects, who required anticoagulation therapy for a variety of medical conditions, were treated for 4 consecutive weeks with Sulindac at varying dosages (200-400 mg per day). Prothrombin time, Thrombotest and bleeding time were not significantly affected by the concurrent administration of Sulindac. It can be concluded that there is no clinically important interaction between phenprocoumon and the doses of sulindac that are considered effective in rheumatic disorders. There were some moderate side effects, only one drop out was registered because of gastro-intestinal bleeding (melaena).
Assuntos
4-Hidroxicumarinas/administração & dosagem , Coagulação Sanguínea/efeitos dos fármacos , Indenos/efeitos adversos , Femprocumona/administração & dosagem , Sulindaco/efeitos adversos , Idoso , Testes de Coagulação Sanguínea , Doenças Cardiovasculares/tratamento farmacológico , Interações Medicamentosas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Reumáticas/tratamento farmacológico , Sulindaco/administração & dosagemRESUMO
The effect of various hormonal contraceptives on the thyroid hormone level, plasmatic and thrombocytic coagulation, cholesterol and ceruloplasmin levels and the activity of gamma-glutamyl transpeptidase was investigaged by the changes produced by long term cyclic estrogen-gestagen therapy on the metabolism of the organism. The free thyroxine index and the total cholesterol were within the normal range. The thyroxine binding index at 44% was above the normal level and the mean value was significantly raised. The ceruloplasmin concentration in the serum was also significantly increased. Pointers to a general hypercoagulability could not be ascertained with a statistical significance.
Assuntos
Coagulação Sanguínea/efeitos dos fármacos , Ceruloplasmina/metabolismo , Colesterol/sangue , Anticoncepcionais Orais Hormonais/farmacologia , Anticoncepcionais Orais/farmacologia , Tiroxina/sangue , Adolescente , Adulto , Etinilestradiol/farmacologia , Fator V , Fator X , Feminino , Fibrinogênio , Humanos , Mestranol/farmacologia , Pessoa de Meia-Idade , Progestinas/farmacologia , Protrombina , Tromboelastografia , Tromboplastina , Testes de Função TireóideaRESUMO
Patients with non-toxic goitre, or patients after an operation of non-toxic goitre, were given 75 mug thyroxine daily. The level of TSH decreased significantly only for the non-toxic goitre group. The TSH-TRH-test showed a high percentage of abnormal results, even after several months of treatment. An index for free thyroxine increased a little, but significantly. The neck sizes decreased only in the post-operative group significantly. The final scans showed a high percentage of goitres. 75 mug thyroxine is too small a dosage in these patients and 100 to 150 mug daily seem to be indicated in the above mentioned states.
